Skip to main content
SpringerLink
Log in

Schwerpunkt "Knochentumoren"

Aktuelle Überlegungen zur System- und Lokaltherapie beim Ewing-Sarkom*

  • Schwerpunkt
  • Published:
InFo Hämatologie + Onkologie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

1
2

Literatur

  1. Chan RC et al. Management and results of localized Ewing's sarcoma. Cancer. 1979;43(3):1001-6

  2. Burgert EO Jr. et al. Multimodal therapy for the management of nonpelvic, localized Ewing's sarcoma of bone: intergroup study IESS-II. J Clin Oncol. 1990;8(9):1514-24

  3. Craft AW et al. Long-term results from the first UKCCSG Ewing's tumour study (ET-1). United Kingdom children's cancer study group (UKCCSG) and the medical research council bone sarcoma working party. Eur J Cancer. 1997;33(7):1061-9

  4. Evans RG et al. Multimodal therapy for the management of localized Ewing's sarcoma of pelvic and sacral bones: a report from the second intergroup study. J Clin Oncol. 1991;9(7):1173-80

  5. Wexler LH et al. Ifosfamide and etoposide plus vincristine, doxorubicin, and cyclophosphamide for newly diagnosed Ewing's sarcoma family of tumors. Cancer. 1996;78(4):901-11

  6. Grier HE et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med. 2003;348(8):694-701

  7. Le Deley MC et al. Cyclophosphamide compared with ifosfamide in consolidation treatment of standard-risk Ewing sarcoma: results of the randomized noninferiority Euro-EWING99-R1 trial. J Clin Oncol. 2014;32(23):2440-8

  8. Paulussen M et al. Results of the EICESS-92 study: two randomized trials of Ewing's sarcoma treatment—cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients. J Clin Oncol. 2008;26(27):4385-93

  9. Andreou D et al. Interdisciplinary diagnostic and treatment of bone sarcomas of the extremities and trunk. Handchir Mikrochir Plast Chir. 2015;47(2):90-9

  10. Strauss SJ et al. Bone sarcomas: ESMO-EURACAN-GENTURIS-ERN PaedCan clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2021;32(12):1520-36

  11. Foulon S et al. Can postoperative radiotherapy be omitted in localised standard-risk Ewing sarcoma? An observational study of the Euro E.W.I.N.G group. Eur J Cancer. 2016;61:128-36

  12. Hesla AC et al. Current status of management and outcome for patients with ewing sarcoma. Cancers (Basel). 2021;13(6):1202

  13. Laskar S et al. Radiotherapy dose escalation in unresectable ewing's sarcoma/PNET: final results of a phase III randomized controlled trial. Int J Radiat Oncol Biol Phys. 2019;105(Issue 1, Supplement,):S62

  14. Paulino AC et al. Dose response and local control using radiotherapy in non-metastatic Ewing sarcoma. Pediatr Blood Cancer. 2007;49(2):145-8

  15. Talleur AC et al. Limited margin radiation therapy for children and young adults with Ewing sarcoma achieves high rates of local tumor control. Int J Radiat Oncol Biol Phys. 2016;96(1):119-26

  16. Laskar S et al. Radiation Therapy Dose Escalation in Unresectable Ewing Sarcoma: Final Results of a Phase 3 Randomized Controlled Trial. Int J Radiat Oncol Biol Phys. 2022;113(5):996-1002

  17. Andreou D et al. Which factors are associated with local control and survival of patients with localized pelvic ewing's sarcoma? A retrospective analysis of data from the Euro-EWING99 trial. Clin Orthop Relat Res. 2020;478(2):290-302

  18. Granowetter L et al. Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors: a children's oncology group study. J Clin Oncol. 2009;27(15):2536-41

  19. Grünewald TGP et al. Ewing sarcoma. Nat Rev Dis Primers. 2018;4(1):5

  20. Schuck A et al. Local therapy in localized Ewing tumors: results of 1058 patients treated in the CESS 81, CESS 86, and EICESS 92 trials. Int J Radiat Oncol Biol Phys. 2003;55(1):168-77

  21. Bedetti B et al. Local control in Ewing sarcoma of the chest wall: results of the EURO-EWING 99 trial. Ann Surg Oncol. 2015;22(9):2853-9

  22. Dunst J, Schuck A. Role of radiotherapy in Ewing tumors. Pediatr Blood Cancer. 2004;42(5):465-70

  23. Dirksen U et al. High-dose chemotherapy compared with standard chemotherapy and lung radiation in ewing sarcoma with pulmonary metastases: results of the European ewing tumour working initiative of national groups, 99 trial and EWING 2008. J Clin Oncol. 2019;37(34):3192-202

  24. Elghazawy H et al. Whole lung irradiation for completely responding pulmonary metastases in pediatric Ewing sarcoma. Future Oncol. 2020;16(15):1043-51

  25. Cunningham DA et al. Proton Whole-Lung Irradiation: Initial Report of Outcomes. Int J Radiat Oncol Biol Phys. 2023;115(4):866-72

  26. Bölling T et al. Radiation toxicity following busulfan/melphalan high-dose chemotherapy in the EURO-EWING-99-trial: review of GPOH data. Strahlenther Onkol. 2009;185 Suppl 2:21-2

  27. Luksch R et al. Primary metastatic Ewing's family tumors: results of the Italian sarcoma group and Scandinavian sarcoma group ISG/SSG IV study including myeloablative chemotherapy and total-lung irradiation. Ann Oncol. 2012;23(11):2970-6

  28. Seddon BM et al. Fatal radiation myelopathy after high-dose busulfan and melphalan chemotherapy and radiotherapy for Ewing's sarcoma: a review of the literature and implications for practice. Clin Oncol (R Coll Radiol). 2005;17(5):385-90

  29. Haeusler J et al. The value of local treatment in patients with primary, disseminated, multifocal Ewing sarcoma (PDMES). Cancer. 2010;116(2):443-50

  30. Rao AD et al. Practice patterns of palliative radiation therapy in pediatric oncology patients in an international pediatric research consortium. Pediatr Blood Cancer. 2017;64(11)

  31. Scobioala S et al. Impact of whole lung irradiation on survival outcome in patients with lung relapsed Ewing sarcoma. Int J Radiat Oncol Biol Phys. 2018;102(3):584-92

  32. Womer RB et al. Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the children's oncology group. J Clin Oncol. 2012;30(33):4148-54

  33. Leavey PJ et al. Phase III trial adding vincristine-topotecan-cyclophosphamide to the initial treatment of patients with nonmetastatic ewing sarcoma: a children's oncology group report. J Clin Oncol. 2021;39(36):4029-38

  34. Brennan B et al. Comparison of two chemotherapy regimens in Ewing sarcoma (ES): overall and subgroup results of the Euro Ewing 2012 randomized trial (EE2012). J Clin Oncol. 2020;38(15_suppl):11500

  35. Whelan J et al.High-Dose Chemotherapy and Blood Autologous Stem-Cell Rescue Compared With Standard Chemotherapy in Localized High-Risk Ewing Sarcoma: Results of Euro-E.W.I.N.G.99 and Ewing-2008. J Clin Oncol. 2018;36(31):3110-9

  36. Dirksen U et al. Efficacy of busulfan-melphalan high dose chemotherapy consolidation (BuMel) compared to conventional chemotherapy combined with lung irradiation in ewing sarcoma (ES) with primary lung metastases: Results of EURO-EWING 99-R2pulm randomized trial (EE99R2pul). J Clin Oncol. 2016;34(15_suppl):11001

  37. Dirksen U et al. Efficacy of add-on treosulfan and melphalan high-dose therapy in patients with high-risk metastatic Ewing sarcoma: report from the international Ewing 2008R3 trial. J Clin Oncol. 2020;38(15_suppl):11501

  38. Ladenstein R et al. Primary disseminated multifocal Ewing sarcoma: results of the Euro-EWING 99 trial. J Clin Oncol. 2010;28(20):3284-91

  39. Toretsky JA, Gorlick R. IGF-1R targeted treatment of sarcoma. Lancet Oncol. 2010;11(2):105-6

  40. Pappo AS, Dirksen U. Rhabdomyosarcoma, Ewing sarcoma, and other round cell sarcomas. J Clin Oncol. 2018;36(2):168-79

  41. Dubois S et al. Randomized phase 3 trial of ganitumab added to interval compressed chemotherapy for patients with newly diagnosed metastatic ewing sarcoma: a report from the children's oncology group (cog). CTOS (Connective Tissue Oncology Society) Annual Meeting. 2019;Abstr 49

  42. Zöllner SK et al. Ewing sarcoma-diagnosis, treatment, clinical challenges and future perspectives. J Clin Med. 2021;10(8):1685

  43. Guenther LM et al. A combination CDK4/6 and IGF1R inhibitor strategy for Ewing sarcoma. Clin Cancer Res. 2019;25(4):1343-57

  44. Attia S et al. A phase II trial of regorafenib (REGO) in patients (pts) with advanced Ewing sarcoma and related tumors (EWS) of soft tissue and bone: SARC024 trial results. J Clin Oncol. 2017;35(15_suppl):11005

  45. Italiano A et al. Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2020;21(3):446-55

  46. Choy E et al. Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy. BMC Cancer. 2014;14:813

  47. Federico SM et al. A phase I trial of talazoparib and irinotecan with and without temozolomide in children and young adults with recurrent or refractory solid malignancies. Eur J Cancer. 2020;137:204-13

  48. Zöllner SK et al. Inhibition of the oncogenic fusion protein EWS-FLI1 causes G(2)-M cell cycle arrest and enhanced vincristine sensitivity in Ewing's sarcoma. Sci Signal. 2017;10(499):eaam8429

  49. Ludwig JA et al. Ewing's sarcoma. N Engl J Med. 2021;384(15):1476

  50. Sankar S et al. Reversible LSD1 inhibition interferes with global EWS/ETS transcriptional activity and impedes Ewing sarcoma tumor growth. Clin Cancer Res. 2014;20(17):4584-97

  51. Untersuchung der Tumorheterogenität am Beispiel Fusionsgetriebener Sarkome www.dekade-gegen-krebs.de/de/wir-ueber-uns/aktuelles-aus-der-dekade/_documents/untersuchung-der-tumorheterogenitaet.htm abgerufen am 2. März 2023

  52. Enneking WF, Dunham WK. Resection and reconstruction for primary neoplasms involving the innominate bone. J Bone Joint Surg Am. 1978;60(6):731-46

  53. Bosma SE et al. Can navigation improve the ability to achieve tumor-free margins in pelvic and sacral primary bone sarcoma resections? A historically controlled study. Clin Orthop Relat Res. 2019;477(7): 1548-59

  54. Dirksen U et al. Association of treatment delays with an unfavorable outcome in patients with localized Ewing sarcoma: a retrospective analysis of data from the GPOH Euro E.W.I.N.G. 99 trial. J Clin Oncol. 2021;39(15_suppl):11502

  55. Gaspar N et al. Ewing sarcoma: current management and future approaches through collaboration. J Clin Oncol. 2015;33(27):3036-46

  56. Gerrand C et al. Seeking international consensus on approaches to primary tumour treatment in Ewing sarcoma. Clin Sarcoma Res. 2020;10(1):21

  57. Ahmed SK et al. Analysis of Local Control Outcomes and Clinical Prognostic Factors in Localized Pelvic Ewing Sarcoma Patients Treated With Radiation Therapy: A Report From the Children's Oncology Group. Int J Radiat Oncol Biol Phys. 2023;115(2):337-46

  58. Hesla AC et al. Improved prognosis for patients with Ewing sarcoma in the sacrum compared with the innominate bones: the Scandinavian sarcoma group experience. J Bone Joint Surg Am. 2016;98(3):199-210

  59. Bosma SE et al. Individual risk evaluation for local recurrence and distant metastasis in Ewing sarcoma: a multistate model: a multistate model for ewing sarcoma. Pediatr Blood Cancer. 2019;66(11):e27943

  60. Arnold MT et al. Is High-dose Radiation Therapy Associated With Early Revision Due to Aseptic Loosening in Patients With a Sarcoma of the Lower Extremities Reconstructed With a Cemented Endoprosthesis? Clin Orthop Relat Res. 2023;481(3):475-87

  61. Mounessi FS et al. Pelvic Ewing sarcomas. Three-dimensional conformal vs. intensity-modulated radiotherapy. Strahlenther Onkol. 2013;189(4):308-14

  62. Su Z et al. Impact of different treatment techniques for pediatric Ewing sarcoma of the chest wall: IMRT, 3DCPT, and IMPT with/without beam aperture. J Appl Clin Med Phys. 2020;21(6):100-7

  63. Delaney et al. Advanced-technology radiation therapy in the management of bone and soft tissue sarcomas. Cancer Control. 2005;12(1):27-35

  64. Keole S et al. Proton therapy for sarcomas. Cancer J. 2014;20(6):409-14

Download references

Author information

Authors and Affiliations

  1. Klinik für Partikeltherapie, WPE, WTZ, (DKTK, Universitätsklinikum Essen, Hufelandstr. 55, 45147, Essen, Deutschland

    Beate Timmermann

  2. Universitätsklinik für Orthopädie und Traumatologie, Medizinische Universität Graz, Auenbruggerplatz 5/6, 8036, Graz, Österreich

    Dimosthenis Andreou

  3. Klinik für Kinderheilkunde III,, Universitätsklinikum Essen, Westdeutsches Tumorzentrum (WTZ, Hufelandstr. 55, 45122, Essen, Deutschland

    Uta Dirksen

Authors
  1. Beate Timmermann
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dimosthenis Andreou
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Uta Dirksen
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Timmermann, B., Andreou, D. & Dirksen, U. Aktuelle Überlegungen zur System- und Lokaltherapie beim Ewing-Sarkom*. InFo Hämatol Onkol 26, 16–21 (2023). https://doi.org/10.1007/s15004-023-9871-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15004-023-9871-7

Search

Navigation